O
ONL Therapeutics
Biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors
About ONL Therapeutics
ONL Therapeutics, established in 2011, is a clinical-stage biopharmaceutical company spun out from the University of Michigan. The company's formation was inspired by the clinical work of its co-founder, Dr. David Zacks, a retina specialist at the University of Michigan's Kellogg Eye Center. Dr. Zacks' research into the molecular mechanisms of photoreceptor cell death led to the discovery of the Fas receptor's critical role in the process and the potential for a therapeutic that could block this pathway to preserve vision. This foundational science, focused on a desire to provide more tools for patients facing vision loss, propelled the company's creation with the help of the university's technology transfer office.
The company's business is centered on developing a portfolio of first-in-class therapies to protect retinal cells from Fas-mediated death, a common pathway in numerous retinal diseases. This positions ONL Therapeutics to address significant unmet medical needs across a spectrum of acute and chronic ophthalmic conditions. The business model involves advancing its lead therapeutic candidate, ONL1204, through rigorous clinical trials to gain regulatory approval and eventual commercialization. Revenue generation will be contingent on the successful development, approval, and marketing of its drug candidates, or through strategic partnerships with larger pharmaceutical companies. ONL has successfully raised substantial capital through multiple funding rounds, including a $46.9 million Series B in 2020 and a $65 million Series D in 2024, attracting investment from notable entities like Johnson & Johnson Innovation – JJDC, Novartis Venture Fund, and Bios Partners.
ONL's core product is ONL1204, a small peptide Fas inhibitor administered via intravitreal injection. Its primary function is to block the Fas receptor on retinal cells, which prevents the activation of both cell death (apoptosis) and inflammatory signaling pathways. This neuroprotective mechanism is designed to preserve retinal cell structure and function. A key benefit is its mutation-independent approach, potentially offering a therapeutic solution for various retinal diseases regardless of their genetic origin. The company's clinical development program is robust, with ONL1204 being evaluated for several indications. It has been granted Orphan Drug Designation by the FDA for the treatment of retinal detachment, an acute condition. Furthermore, ONL is actively conducting clinical trials for chronic conditions, including a Phase 2 study for geographic atrophy (GA) associated with age-related macular degeneration (AMD) and a Phase 1b trial for progressing open-angle glaucoma. Early clinical data has been encouraging, showing that ONL1204 can reduce the growth rate of GA lesions and has demonstrated potential for neuroenhancement in glaucoma patients.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2011
- Headquarters
- Ann Arbor, United States
- Employees
- 37
- Open positions
- None listed
- Dealroom signal
- 33.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- B2B
- Investment activity
- 1 company, latest Dec 2020
- Capital deployed
- $47M
- Preferred round
- SERIES B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Sep 2024 | $65M | $260M | Visionary Ventures · Novartis Venture Fund · Bios Partners · Johnson & Johnson Innovation | ↗ |
| SERIES COther financing | Mar 2023 | $15M | $235M | Bios Partners · Capital Community Angel Investors · Western Michigan University · PSQ Capital | ↗ |
Growth signals
Latest recorded traffic for ONL Therapeutics is 3.6K monthly website visits, up 71.4% over the last three months. ONL Therapeutics's team declined 2.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
ONL Therapeutics in the Ann Arbor ecosystem
The ONL Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Capital Community Angel Investors
National Institutes of Health
National Eye Institute
Series A12 investors entered at this stage
InvestMichigan
Novartis
Western Michigan University
Invest Michigan
Bios Partners- KCKaitai Capital
Michigan Capital Network
ONL Therapeutics
Johnson & Johnson Innovation
InFocus Capital Partners- PCPSQ Capital
Biosciences Research and Commercialization Center
Series B and later5 investors entered at this stage
ExSight Ventures
Alpine Visionary Venture- VVVisionary Ventures
Mayewell Capital
Novartis Venture Fund
Other known investors1 additional known investor
University of Michigan
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ONL Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ONL Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








